Dernières nouvelles pour Axsome Therapeutics (NASDAQ:AXSM) Stock

AXSOME THERAPEUTICS INC

Axsome Therapeutics

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics Inc

<ul>
<li>Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation&nbsp;</li>
<li>Presentation featuring network meta-analysis of SYMBRAVO versus oral CGRPs</li>
</ul>

Biotech

News

Health Care

General

AXSM

Axsome Therapeutics Announced Multiple Presentations At The 2025 American Academy Of Neurology Annual Meeting

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $200 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $200 Price Target

WIIM

Axsome Therapeutics shares are trading lower after the company's Solriamfetol failed its primary goal in depression study but showed improvements in associated sleep disorder.

Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) on Tuesday released results of the PARADIGM Phase 3 proof-of-concept trial of solriamfetol in major depressive disorder (MDD) with and without severe excessive <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">daytime sleepiness (EDS)</a>.
In the overall patient population, the study did not demonstrate a statistically significant change on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared to placebo, the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44581422/axsome-therapeutics-announces-topline-results-of-paradigm-phase-3-proof-of-concept-trial-of-solria" rel="noreferrer noopener">study&#8217;s primary endpoint</a>.
In the prespecified subgroup of patients with severe EDS, treatment with solriamfetol resulted in greater improvements in depressive symptoms compared to placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44475435/axsome-therapeutics-lower-dose-of-attention-deficient-disorder-candidate-hits-primary-goal" rel="noreferrer noopener">Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal</a>
The study was not powered to demonstrate statistical significance in the prespecified subgroups.
Based on the results in the EDS subgroup, Axsome plans to initiate a Phase 3 trial in MDD patients with EDS in 2025.
Solriamfetol was safe and well-tolerated in the trial, with a side effect profile consistent with the established safety profile.
William Blair notes that Axsome already sells Auvelity for MDD.
To prevent competition between its drugs, the company had planned to market solriamfetol specifically to MDD patients who also experience EDS, a common issue in MDD.
Because of this strategy, the limited efficacy signal in the EDS subgroup is not seen as a drawback for the drug's commercial potential.
While the positive results in MDD patients with severe EDS are promising and align with solriamfetol's known effects—it is already sold as Sunosi for EDS linked to obstructive sleep apnea—the PARADIGM study only included a small group of 51 patients.
Larger Phase 3 studies will be needed to confirm these findings.
Analyst Myles Minter writes, &#8220;Axsome remains our top pick for 2025. With focus for the company on Auvelity in MDD and an sNDA filing for Alzheimer's disease agitation (AD-A), we believe investor expectations were low for the PARADIGM study, and expect few had factored the opportunity into their valuations.&#8221;
Price Action: AXSM stock is down 4.41% at $111.49&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44585627/conagra-embraces-bloom-energys-fuel-cells-to-power-ohio-operations" target="_blank" rel="noreferrer noopener">Conagra Embraces Bloom Energy&#8217;s Fuel Cells To Power Ohio Operations</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $153 price target.

Needham Reiterates Buy on Axsome Therapeutics, Maintains $153 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo raised Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) price target from $184 to $186. Wells Fargo analyst Jason Haas maintained an Underweight rating. Cintas shares closed at $204.71 on Wednesday. See how other <a href="https://www.benzinga.com/quote/CTAS/analyst-ratings">analysts view this stock</a>.</li>
<li>Mizuho raised the price target for Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) from $212 to $216. Mizuho analyst Graig Suvannavejh maintained an Outperform rating. Axsome Therapeutics shares closed at $119.16 on Wednesday. <a href="https://www.benzinga.com/quote/AXSM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Paychex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) price target from $141 to $156. Stifel analyst Bryan Bergin maintained a Hold rating. Paychex shares closed at $150.19 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/PAYX/analyst-ratings">view this stock</a>.</li>
<li>Piper Sandler raised the price target for Mondelez International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) from $56 to $59. Piper Sandler analyst Michael Lavery maintained a Neutral rating. Mondelez shares closed at $66.33 on Wednesday. <a href="https://www.benzinga.com/quote/MDLZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank increased the price target for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from $70 to $75. Deutsche Bank analyst David Begleiter maintained a Buy rating. Celanese shares closed at $59.16 on Wednesday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham cut Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) price target from $240 to $215. Needham analyst Gerald Pascarelli maintained a Buy rating. Constellation shares settled at $184.11 on Wednesday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) price target from $230 to $260. B of A Securities analyst Tal Liani upgraded the stock from Neutral to Buy. Check Point Software shares closed at $227.87 on Wednesday. <a href="https://www.benzinga.com/quote/CHKP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group increased Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $75 to $82. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Dollar Tree shares closed at $69.21 on Wednesday.  <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut the price target for Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from $135 to $120. Jefferies analyst Blayne Curtis downgraded the stock from Buy to Hold. AMD shares settled at $110.19 on Wednesday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) price target from $265 to $260. Wells Fargo analyst Christian Wetherbee maintained an Overweight rating. Union Pacific shares closed at $238.03 on Wednesday. <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44496478/top-2-industrials-stocks-that-may-crash-in-q1">Top 2 Industrials Stocks That May Crash In Q1</a></li>
</ul>

CHKP

CTAS

DLTR

MDLZ

PAYX

Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday

Ratings for Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) were provided by 31 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">18</td>
<td align="right">13</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">10</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $168.71, along with a high estimate of $216.00 and a low estimate of $122.00. Marking an increase of 9.04%, the current average surpasses the previous average price target of $154.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1743080430_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Axsome Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$216.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$192.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$153.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$176.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Marc Goodman</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Axsome Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Axsome Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>About Axsome Therapeutics</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Financial Milestones: Axsome Therapeutics's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 66.04%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -63.08%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -99.94%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 3.38. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $212 to $216.

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $216

On Tuesday, Axsome Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) announced that the FOCUS Phase 3 trial of solriamfetol for attention deficit hyperactivity disorder (ADHD) achieved its primary and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">key secondary endpoints</a>.
In the FOCUS study, 516 adults with ADHD were randomized to receive solriamfetol 150 mg, solriamfetol 300 mg, or placebo, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44470498/axsome-therapeutics-announces-focus-phase-3-trial-of-solriamfetol-in-adults-with-attention-deficit" rel="noreferrer noopener">once daily for 6 weeks</a>.
The study achieved the primary endpoint by demonstrating a statistically significant reduction in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score compared to placebo at Week 6, with mean reductions from baseline of 17.7 points for solriamfetol 150 mg and 14.3 points for placebo (p=0.039).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43921470/axsome-says-symbravo-hits-primary-goal-in-late-stage-migraine-trial-in-patients-experiencing-inadequate-response-to-commonly-used-drugs" rel="noreferrer noopener">Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs</a>
Overall, the improvement with solriamfetol at Week 6 represents a 45% mean reduction from baseline in ADHD symptoms.
Improvements in the AISRS total score were greater with solriamfetol compared to placebo starting at Week 1 (p=0.036).
Clinical response, defined as ≥30% improvement from baseline in the AISRS total score, was achieved by a statistically significantly greater percentage of patients treated with solriamfetol 150 mg (53.5%) compared to those treated with placebo (41.3%) at Week 6 (p=0.024).
The study also achieved the key secondary endpoint by statistically significantly reducing overall ADHD disease severity compared to placebo, as assessed by the Clinical Global Impression of Severity (CGI-S) for ADHD, at Week 6 (p=0.017).
Results on the primary and key secondary endpoints for the exploratory 300 mg solriamfetol dose were numerically superior compared to placebo but were not statistically significant.
Solriamfetol was safe and well tolerated in the trial.
Price Action: AXSM stock is down 5.27% at $122.36 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44462549/lockheed-martin-stock-dips-as-bofa-analyst-lowers-eps-estimates-forecast-after-air-force-contract-setback" target="_blank" rel="noreferrer noopener">Lockheed Martin Stock Dips As BofA Analyst Lowers EPS Estimates, Forecast After Air Force Contract Setback</a></li>
</ul>

Movers

Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal

<ul>
<li>Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039, primary endpoint, 150 mg solriamfetol)</li>
<li>Statistically significant reduction in overall ADHD disease severity as measured by the CGI-S score compared to placebo (p=0.017, key secondary endpoint, 150 mg solriamfetol)</li>
<li>Statistically significant rate of clinical response on the AISRS compared to placebo (p=0.024, 150 mg solriamfetol)</li>
<li>Onset of action as early as Week 1 compared to placebo (p=0.036, AISRS, 150 mg solriamfetol)</li>
<li>Well tolerated with safety profile generally consistent with prior solriamfetol trials</li>
</ul>

Axsome Therapeutics' Says FOCUS Phase 3 Trial Of Solriamfetol In The Treatment Of Attention Deficit Hyperactivity Disorder Achieved Its Primary And Key Secondary Endpoints Demonstrating Statistically Significant Improvements In Symptoms And Disease Severity Compared To Placebo

Legal

Axsome Therapeutics Announced That It Has Entered Into A Settlement Agreement With Hikma Pharmaceuticals Usa, Inc. Resolving Patent Litigation Related To Axsome's Product Sunosi (Solriamfetol)

Baird analyst Joel Beatty maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $132 to $160.

Baird Maintains Outperform on Axsome Therapeutics, Raises Price Target to $160

Based on the feedback from the FDA, the Company's regulatory data package would be sufficient for the submission of an sNDA for AXS-05 for the treatment of Alzheimer's disease agitation. Axsome anticipates submitting the planned sNDA in the third quarter of 2025. Acceptance of the final sNDA will be subject to the FDA's review of the complete filing. AXS-05 was granted Breakthrough Therapy designation for the treatment of Alzheimer's disease agitation in June 2020.

Axsome Therapeutics Received Formal Pre-New Drug Application Meeting Minutes From The FDA Supporting A Supplemental Application Submission For AXS-05 In Alzheimer's Disease Agitation

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">16</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">11</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.07, a high estimate of $212.00, and a low estimate of $121.00. This upward trend is apparent, with the current average reflecting a 9.62% increase from the previous average price target of $150.59.
<img src="https://www.benzinga.com/files/images/story/2025/1740664869_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Axsome Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$212.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$192.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$153.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$153.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$176.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Marc Goodman</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$150.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$139.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$122.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$121.00</td>
<td>$121.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Axsome Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>Delving into Axsome Therapeutics's Background</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Understanding the Numbers: Axsome Therapeutics's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 66.04%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Axsome Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -63.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -99.94%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.26%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.38, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)

Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Overweight and raises the price target from $125 to $190.

Morgan Stanley Maintains Overweight on Axsome Therapeutics, Raises Price Target to $190

Mizuho analyst Graig Suvannavejh maintains Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Outperform and raises the price target from $195 to $212.

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $212

On Monday, Axsome Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) announced that the EMERGE Phase 3 trial of Symbravo&nbsp;(MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43908665/axsome-therapeutics-announces-symbravo-meloxicam-and-rizatriptan-achieves-primary-endpoint-in-the-" rel="noreferrer noopener">met its primary endpoint</a>.
Symbravo demonstrated statistically significantly greater migraine treatment response than oral CGRP inhibitors, as measured by the Migraine Treatment Optimization Questionnaire (mTOQ-4) (5.2 versus 2.8, p&lt;0.001).
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/02/43790716/axsomes-axs-05-in-alzheimers-agitation-could-be-billion-dollar-opportunity-says-analyst" rel="noreferrer noopener">Axsome&#8217;s AXS-05 In Alzheimer&#8217;s Agitation Could Be Billion Dollar Opportunity, Says Analyst</a>
In the trial, Symbravo rapidly and substantially improved migraine pain and most bothersome symptoms.
Statistically significantly greater proportions of patients achieved clinical response on the 2-hour pain freedom, sustained pain freedom, ability to return to normal activities, and ability to plan daily activities mTOQ-4 items with Symbravo compared to oral CGRP inhibitors:
<ul>
<li>Pain freedom within 2 hours for most attacks was reported half the time or more by 47.9% of patients after treatment with Symbravo, compared to 1.0% of patients after treatment with oral CGRPs.</li>
<li>Sustained relief of migraine pain for at least 24 hours following a single dose of medication was reported half the time or more by 47.9% of patients after treatment with Symbravo, compared to 16.7% of patients after treatment with oral CGRPs.</li>
<li>The ability to quickly return to normal activities after taking their medication was reported half the time or more by 51.0% of patients after treatment with Symbravo, compared to 11.5% of patients after treatment with oral CGRPs.</li>
<li>The proportion of patients who reported being comfortable enough with their medication to be able to plan daily activities half the time or more was 63.5% after treatment with Symbravo, compared to 26.0% after treatment with oral CGRPs.</li>
</ul>
Price Action: AXSM stock is down 4.82% at $131.12 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43911212/tiktok-collaboration-powers-connexas-new-mena-strategy-stocks-skyrocket" target="_blank" rel="noreferrer noopener">TikTok Collaboration Powers Connexa&#8217;s New MENA Strategy</a></li>
</ul>

Trading Ideas

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Press Releases

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation

Earnings

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Axsome Therapeutics

Actualités

Dernières nouvelles pour Axsome Therapeutics (NASDAQ:AXSM) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL